FDAnews Drug Daily Bulletin

MERCK KGAA BUYS DANISH BIOTECH CO SURVAC FOR 11 MLN EUR TO BOOST PIPELINE

Nov. 21, 2005
A A

Merck KGaA said it has acquired the Danish biotechnology company Survac ApS for 11 mln eur, in a move to gain access to new technologies for cancer treatment for its drugs pipeline. The acquisition should be completed this year. Merck said Survac has developed a technology to identify and modify peptides that are useful for therapeutic cancer vaccines.

Forbes (http://www.forbes.com/markets/feeds/afx/2005/11/18/afx2345687.html)